welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac in Patients With Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc., a private biotech company developing novel therapeutics to prevent cancer and other diseases, and its partner Mallinckrodt Plc, a leading global specialty pharmaceutical company, today announced that CPP’s pivotal phase 3 clinical trial, CPP FAP-310, of the investigational drug CPP-1X/sulindac in patients with familial adenomatous polyposis (FAP), did not meet its primary endpoint. Specifically, the reduction of time to the first occurrence of an FAP-related event for the combination of CPP-1X (eflornithine) and sulindac (a nonsteroidal anti-inflammatory drug) did not reach statistical significance compared to the two control arms. CPP FAP-310 included only active comparator arms and was the largest and longest study ever conducted in patients with FAP.
“While we are disappointed that the CPP FAP-310 clinical trial did not achieve its primary endpoint, we are encouraged by the data that relate to important outcome measures,” said CPP CEO Jeff Jacob.
expertly curated content related to this topic
-
Live Chat About the FAP 310 Clinical Trialhttps://www.youtube.com/watch?v=tKHUFgyO...
-
Study identifies enhanced impact of treatment for hereditary cancer patientsPeople with an inherited syndrome called...
-
Prostanoids, Ornithine Decarboxylase, and Polyamines in Primary Chemoprevention of Familial Adenomatous PolyposisBACKGROUND & AIMS : Familial adenoma...
-
Cancer Prevention Pharmaceuticals Announces NEJM Publication of Landmark Phase 3 Clinical Trial for Treatment of Fam...Cancer Prevention Pharmaceuticals, Inc. ...
-
Sulindac Sulfone Induced Regression of Rectal Polyps in Patients with Familial Adenomatous PolyposisSulindac sulfone (Exisulind), a metaboli...
-
Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) PatientsMalignant transformation of adenomas of ...
-
Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Developm...Sucampo Pharmaceuticals, Inc., a global ...